Note that this trial is an early trial primarily designed to investigate safety of the treatment. It’s absolutely good news but they need to do a stage 3 trial with a much larger N to convincingly show that it has such a large effect.
But sure, the study design and primary/secondary endpoints are always levers to increase likelihood of admission. There are often long discussions with the FDA and other regulators on how the endpoints and study population should look like.